RecruitingPhase 2NCT04560322

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

A Phase 2 Study of MRD Adapted Therapy With Venetoclax-obinutuzumab in Patients With High or Intermediate BALL Risk Relapsed or Refractory CLL, With Addition of Acalabrutinib in Patients Who Fail to Achieve MRD Eradication

Sponsor

Massachusetts General Hospital

Enrollment

40 participants

Start Date

Oct 19, 2020

Study Type

INTERVENTIONAL

Conditions

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Summary

This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: * obinutuzumab * venetoclax * acalabrutinib

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests combining three targeted cancer drugs — venetoclax, obinutuzumab, and acalabrutinib — for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to treatment. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of CLL or SLL - Your cancer requires treatment and is classified as high or intermediate risk - You have received at least one prior treatment for CLL - You are in reasonably good health and your liver, kidneys, and bone marrow are functioning adequately **You may NOT be eligible if...** - Your CLL is low risk and does not yet require treatment - You have never been treated for CLL before - You have significant organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.